CLINICAL_TRIALS
trial_result
· 2007-11-28
Clinical Trial Update: A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration [Phase 2]
Summary
A Phase 2 study of MSI-1256F (squalamine lactate) for wet age-related macular degeneration was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genaera Corporation | Conditions: Macular Degeneration | Phase 2 | Status: TERMINATED